|
1
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: Metabolic reprogramming
fuels cell growth and proliferation. Cell Metabolism. 7:11–20.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Warburg O, Wind F and Negelein E: The
metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H,
Zha Z, Liu Y, Li Z, Xu Y, et al: Acetylation targets the M2 isoform
of pyruvate kinase for degradation through chaperone-mediated
autophagy and promotes tumor growth. Mol Cell. 42:719–730. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu XD, Shao SX, Jiang HP, Cao YW, Wang YH,
Yang XC, Wang YL, Wang XS and Niu HT: Warburg effect or reverse
Warburg effect? A review of cancer metabolism. Oncol Res Treat.
38:117–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liesa M and Shirihai OS: Mitochondrial
dynamics in the regulation of nutrient utilization and energy
expenditure. Cell Metab. 17:491–506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mitra K: Mitochondrial fission-fusion as
an emerging key regulator of cell proliferation and
differentiation. Bioessays. 35:955–964. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Youle RJ and Karbowski M: Mitochondrial
fission in apoptosis. Nat Rev Mol Cell Biol. 6:657–663. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo S, Li Y, Ma R, Liu J, Xu P, Zhang H,
Tang K, Ma J, Liu N, Zhang Y, et al: Downregulation of PCK2
remodels tricar-boxylic acid cycle in tumor-repopulating cells of
melanoma. Oncogene. 36:3609–3617. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kerins MJ, Vashisht AA, Liang BX,
Duckworth SJ, Praslicka BJ, Wohlschlegel JA and Ooi A: Fumarate
mediates a chronic prolif-erative signal in fumarate
Hydratase-inactivated cancer cells by increasing transcription and
translation of ferritin genes. Mol Cell Biol. 37:pii: e00079-e17.
2017, View Article : Google Scholar
|
|
12
|
Crunkhorn S: Breast cancer: Inhibiting
fatty acid oxidation blocks tumour growth. Nat Rev Drug Discov.
15:3102016.
|
|
13
|
Zhu L, Ploessl K, Zhou R, Mankoff D and
Kung HF: Metabolic imaging of glutamine in cancer. J Nucl Med.
58:533–537. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Csibi A, Fendt SM, Li C, Poulogiannis G,
Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T,
et al: The mTORC1 pathway stimulates glutamine metabolism and cell
proliferation by repressing SIRT4. Cell. 153:840–854. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Altman BJ, Stine ZE and Dang CV: From
Krebs to clinic: Glutamine metabolism to cancer therapy. Nat Rev
Cancer. 16:619–634. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tedeschi PM, Bansal N, Kerrigan JE, Abali
EE, Scotto KW and Bertino JR: NAD+ kinase as a therapeutic target
in cancer. Clin Cancer Res. 22:5189–5195. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang P, Du W, Wang X, Mancuso A, Gao X,
Wu M and Yang X: p53 regulates biosynthesis through direct
inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol.
13:310–316. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dang CV: Rethinking the Warburg effect
with Myc micromanaging glutamine metabolism. Cancer Res.
70:859–862. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang JB, Erickson JW, Fuji R, Ramachandran
S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV and
Cerione RA: Targeting mitochondrial glutaminase activity inhibits
oncogenic transformation. Cancer Cell. 18:207–219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao P, Tchernyshyov I, Chang TC, Lee YS,
Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT and
Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial
glutaminase expression and glutamine metabolism. Nature.
458:762–765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Poulain L, Sujobert P, Zylbersztejn F,
Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R,
Vergez F, et al: High mTORC1 activity drives glycolysis addiction
and sensitivity to G6PD inhibition in acute myeloid leukemia cells.
Leukemia. 31:2326–2335. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oronsky BT, Oronsky N, Fanger GR, Parker
CW, Caroen SZ, Lybeck M and Scicinski JJ: Follow the ATP: Tumor
energy production: A perspective. Anticancer Agents Med Chem.
14:1187–1198. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rah SY and Kim UH: CD38-mediated
Ca2+ signaling contributes to glucagon-induced hepatic
gluconeogenesis. Sci Rep. 5:107412015. View Article : Google Scholar
|
|
24
|
Mehta K, Shahid U and Malavasi F: Human
CD38, a cell-surface protein with multiple functions. FASEB J.
10:1408–1417. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Malavasi F, Funaro A, Roggero S,
Horenstein A, Calosso L and Mehta K: Human CD38: A glycoprotein in
search of a function. Immunol Today. 15:95–97. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chini EN: CD38 as a regulator of cellular
NAD: A novel potential pharmacological target for metabolic
conditions. Curr Pharm Des. 15:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zocchi E, Daga A, Usai C, Franco L, Guida
L, Bruzzone S, Costa A, Marchetti C and De Flora A: Expression of
CD38 increases intracellular calcium concentration and reduces
doubling time in HeLa and 3T3 cells. J Biol Chem. 273:8017–8024.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Long AN, Owens K, Schlappal AE, Kristian
T, Fishman PS and Schuh RA: Effect of nicotinamide mononucleotide
on brain mitochondrial respiratory deficits in an Alzheimer's
disease‑relevant murine model. BMC Neurol. 15:192015. View Article : Google Scholar
|
|
29
|
Hayakawa K, Esposito E, Wang X, Terasaki
Y, Liu Y, Xing C, Ji X and Lo EH: Transfer of mitochondria from
astrocytes to neurons after stroke. Nature. 535:551–555. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liao S, Xiao S, Chen H, Zhang M, Chen Z,
Long Y, Gao L, Zhu G, He J, Peng S, et al: CD38 enhances the
proliferation and inhibits the apoptosis of cervical cancer cells
by affecting the mitochondria functions. Mol Carcinog.
56:2245–2257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liao S, Xiao S, Zhu G, Zheng D, He J, Pei
Z, Li G and Zhou Y: CD38 is highly expressed and affects the
PI3K/Akt signaling pathway in cervical cancer. Oncol Rep.
32:2703–2709. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu GC, Gao L, He J, Long Y, Liao S, Wang
H, Li X, Yi W, Pei Z, Wu M, et al: CD90 is upregulated in gastric
cancer tissues and inhibits gastric cancer cell apoptosis by
modulating the expression level of SPARC protein. Oncol Rep.
34:2497–2506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li H, Li X, Ge X, Jia L, Zhang Z, Fang R,
Yang J, Liu J, Peng S, Zhou M, et al: MiR-34b-3 and miR-449a
inhibit malignant progression of nasopharyngeal carcinoma by
targeting lactate dehydrogenase A. Oncotarget. 7:54838–54851. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Luo P, Zhang C, Liao F, Chen L, Liu Z,
Long L, Jiang Z, Wang Y, Wang Z, Liu Z, et al: Transcriptional
positive cofactor 4 promotes breast cancer proliferation and
metastasis through c-Myc mediated Warburg effect. Cell Commun
Signal. 17:362019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hensley CT, Faubert B, Yuan Q, Lev-Cohain
N, Jin E, Kim J, Jiang L, Ko B, Skelton R, Loudat L, et al:
Metabolic heterogeneity in human lung tumors. Cell. 164:681–694.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kletzien RF, Harris PK and Foellmi LA:
Glucose-6-phosphate dehydrogenase: A 'housekeeping' enzyme subject
to tissue‑specific regulation by hormones, nutrients, and oxidant
stress. FASEB J. 8:174–181. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stanton RC: Glucose-6-phosphate
dehydrogenase, NADPH, and cell survival. IUBMB Life. 64:362–369.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wood T: Physiological functions of the
pentose phosphate pathway. Cell Biochem Funct. 4:241–247. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Compagno M, Lim WK, Grunn A, Nandula SV,
Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano
A, et al: Mutations of multiple genes cause deregulation of
NF-kappaB in diffuse large B-cell lymphoma. Nature. 459:717–721.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rosenwald A, Wright G, Chan WC, Connors
JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland
EB, Giltnane JM, et al: The use of molecular profiling to predict
survival after chemotherapy for diffuse large-B-cell lymphoma. N
Engl J Med. 346:1937–1947. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Quade BJ, Wang TY, Sornberger K, Dal Cin
P, Mutter GL and Morton CC: Molecular pathogenesis of uterine
smooth muscle tumors from transcriptional profiling. Genes
Chromosomes Cancer. 40:97–108. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stearman RS, Dwyer-Nield L, Zerbe L,
Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT,
Franklin WA, et al: Analysis of orthologous gene expression between
human pulmonary adenocarcinoma and a carcinogen-induced murine
model. Am J Pathol. 167:1763–1775. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ,
Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH and Huang CY:
Selection of DDX5 as a novel internal control for Q-RT-PCR from
micro-array data using a block bootstrap re-sampling scheme. BMC
Genomics. 8:1402007. View Article : Google Scholar
|
|
44
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ji H, Ramsey MR, Hayes DN, Fan C, McNamara
K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, et al:
LKB1 modulates lung cancer differentiation and metastasis. Nature.
448:807–810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Son J, Lyssiotis CA, Ying H, Wang X, Hua
S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, et
al: Glutamine supports pancreatic cancer growth through a
KRAS-regulated metabolic pathway. Nature. 496:101–105. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jian M, Yunjia Z, Zhiying D, Yanduo J and
Guocheng J: Interleukin 7 receptor activates PI3K/Akt/mTOR
signaling pathway via downregulation of Beclin-1 in lung cancer.
Mol Carcinog. 58:358–365. 2019. View Article : Google Scholar
|
|
48
|
Lau MT and Leung PC: The PI3K/Akt/mTOR
signaling pathway mediates insulin-like growth factor 1-induced
E-cadherin down-regulation and cell proliferation in ovarian cancer
cells. Cancer Lett. 326:191–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Takeuchi H, Kondo Y, Fujiwara K, Kanzawa
T, Aoki H, Mills GB and Kondo S: Synergistic augmentation of
rapamycin-induced autophagy in malignant glioma cells by
phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer
Res. 65:3336–3346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Barra F, Evangelisti G, Ferro Desideri L,
Di Domenico S, Ferraioli D, Vellone VG, De Cian F and Ferrero S:
Investigational PI3K/AKT/mTOR inhibitors in development for
endometrial cancer. Expert Opin Investig Drugs. 28:131–142. 2019.
View Article : Google Scholar
|
|
52
|
Fleming GF, Filiaci VL, Marzullo B, Zaino
RJ, Davidson SA, Pearl M, Makker V, Burke JJ II, Zweizig SL, Van Le
L, et al: Temsirolimus with or without megestrol acetate and
tamoxifen for endometrial cancer: A gynecologic oncology group
study. Gynecol Oncol. 132:585–592. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Colombo N, McMeekin S, Schwartz P, Kostka
J, Sessa C, Holloway PG, Braly P, Matei D and Einstein M: A phase
II trial of the mTOR inhibitor AP23573 as a single agent in
advanced endometrial cancer. J Clin Oncol. 25(18 Suppl): S55162007.
View Article : Google Scholar
|
|
54
|
Tsoref D, Welch S, Lau S, Biagi J, Tonkin
K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, et al: Phase
II study of oral rida-forolimus in women with recurrent or
metastatic endometrial cancer. Gynecol Oncol. 135:184–189. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tan X, Zhang Z, Yao H and Shen L: Tim-4
promotes the growth of colorectal cancer by activating angiogenesis
and recruiting tumor-associated macrophages via the PI3K/AKT/mTOR
signaling pathway. Cancer Lett. 436:119–128. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lian G, Chen S, Ouyang M, Li F, Chen L and
Yang J: Colon cancer cell secretes EGF to promote M2 polarization
of TAM through EGFR/PI3K/AKT/mTOR pathway. Technol Cancer Res
Treat. 18:15330338198490682019. View Article : Google Scholar : PubMed/NCBI
|
